Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

  title={Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.},
  author={Judith A. M. Wessels and Thomas W. J. Huizinga and H-J. Guchelaar},
  volume={47 3},
This review presents recent data supporting the methotrexate (MTX) mechanisms of action, which are likely to account for its anti-proliferative and immunosuppressive effects in rheumatoid arthritis (RA). The effects of MTX in vivo may be mediated by reducing cell proliferation, increasing the rate of apoptosis of T cells, increasing endogenous adenosine release, altering the expression of cellular adhesion molecules, influencing production of cytokines, humoral responses and bone formation… 

Figures and Tables from this paper

Folates and antifolates in rheumatoid arthritis

An overview will be presented of strategies that may assist in the future design of rationalized and personalized targeted therapies with a folate antagonist.

Current Understanding of Rheumatoid Arthritis Therapy

This review summarizes the pathogenesis‐related rationales for the current therapeutic strategies in RA and for emerging therapies and potential approaches to restoring immune tolerance in RA.

An update on methotrexate

Methotrexate was shown to improve signs and symptoms of RA, disease activity and function, to a similar degree as the tumor necrosis factor blockers, and it inhibits radiographic progression to a smaller degree than the antitumor Necrosis factor agents.

Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis

Methotrexate seems to be one of the safest DMARDs, while there is evidence that patients treated with MTX have lower mortality, especially due to cardiovascular causes.

The future of folic acid antagonist therapy in rheumatoid arthritis.

  • C. Fiehn
  • Medicine
    Arthritis and rheumatism
  • 2009
It should be emphasized that MTX is experiencing a comeback in RA clinical trials, although this drug has several pharmacologic disadvantages that one might think should be limiting its use.

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?

An update is provided on the current data regarding biomarkers of treatment response to MTX and the role of potential biomarkers in predicting treatment effectiveness of MTX.

Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis

A need to rationalize the use of synthetic DMARDs to help improve RA treatment by the construction of suitable models of the disease process, thereby augmenting treatment options and integrating pharmacokinetic and pharmacodynamic properties into this model will help in improving treatment outcomes.

Systemic methotrexate for the treatment of psoriasis

An extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics is made.

Effects of methotrexate on the expression of the translational isoforms of glucocorticoid receptors α and β: correlation with methotrexate efficacy in rheumatoid arthritis patients.

MTX in vitro induces greater expression of GRαAB isoform in PBMC from RA patients who later respond to MTX treatment than in non-responding patients, which may have clinical applications for predicting MTX efficacy in RA patients.

Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis

The mechanism of action of methotrexate, originally developed as a folate antagonist for the treatment of cancer, and its role in the therapy of rheumatoid arthritis are reviewed.

Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis

Several lines of evidence clearly suggest that MTX does not act simply as a cytotoxic (antiproliferative) agent for the cells responsible for the joint inflammation in RA.

Two Inhibitors of DNA‐Synthesis Lead to Inhibition of Cytokine Production via a Different Mechanism

T‐cells are the main target cells of the immunosuppressive drugs MPA and MTX, and the production of T‐cell cytokines was inhibited by both drugs.

Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.

There is strong evidence that adenosine mediates the antiinflammatory effects of MTX in this model of RA, and the findings suggest that abstinence from caffeine, a ubiquitous food additive and medication, may enhance the therapeutic effects ofMTX in RA.

Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage.

Treatment with MTX inhibits the proliferation of primitive marrow stromal cells, but not their ability to undergo osteogenic differentiation, and these findings are reassuring for clinicians using MTX in the treatment of RA.

Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis.

It is shown that there is no impact of effective MTX dose represented by EMTX on blood adenosine concentration in JIA patients and it is likely that local release ofadenosine at inflamed tissues is responsible for its action which may not be reflected by sustained increase of its blood concentration.

Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate

Data support the hypothesis that inhibition of angiogenesis does not significantly contribute to the antiarthritic effect of MTX seen in patients and animal models for RA and the combination ofMTX with antiangiogenic drugs appears to be a rational strategy in the treatment of RA.

Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.

Genetic factors contribute to the antiinflammatory efficacy of MTX, and a single locus involved in MTX-induced adenosine up-regulation is likely responsible for the observed resistance to MTX in DBA/1J mice.

Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis

The hypothesis that activated T cells are preferentially inhibited by leflunomide is supported and may be either inhibition of uridine synthesis or effects on signal transduction pathways.